163 related articles for article (PubMed ID: 28637510)
1. A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type γ in chronic myeloid leukemia patients.
Vezzalini M; Mafficini A; Tomasello L; Lorenzetto E; Moratti E; Fiorini Z; Holyoake TL; Pellicano F; Krampera M; Tecchio C; Yassin M; Al-Dewik N; Ismail MA; Al Sayab A; Monne M; Sorio C
J Hematol Oncol; 2017 Jun; 10(1):129. PubMed ID: 28637510
[TBL] [Abstract][Full Text] [Related]
2. Protein tyrosine phosphatase receptor type {gamma} is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia.
Della Peruta M; Martinelli G; Moratti E; Pintani D; Vezzalini M; Mafficini A; Grafone T; Iacobucci I; Soverini S; Murineddu M; Vinante F; Tecchio C; Piras G; Gabbas A; Monne M; Sorio C
Cancer Res; 2010 Nov; 70(21):8896-906. PubMed ID: 20959494
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients.
Ismail MA; Vezzalini M; Morsi H; Abujaber A; Al Sayab A; Siveen K; Yassin MA; Monne M; Samara M; Cook R; Sorio C; Modjtahedi H; Al-Dewik NI
Sci Rep; 2021 Apr; 11(1):8833. PubMed ID: 33893334
[TBL] [Abstract][Full Text] [Related]
4. Regulative Loop between β-catenin and Protein Tyrosine Receptor Type γ in Chronic Myeloid Leukemia.
Tomasello L; Vezzalini M; Boni C; Bonifacio M; Scaffidi L; Yassin M; Al-Dewik N; Takam Kamga P; Krampera M; Sorio C
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32225105
[TBL] [Abstract][Full Text] [Related]
5. Description of PTPRG genetic variants identified in a cohort of Chronic Myeloid Leukemia patients and their ability to influence response to Tyrosine kinase Inhibitors.
Ismail MA; Nasrallah GK; Monne M; AlSayab A; Yassin MA; Varadharaj G; Younes S; Sorio C; Cook R; Modjtahedi H; Al-Dewik NI
Gene; 2022 Mar; 813():146101. PubMed ID: 34906644
[TBL] [Abstract][Full Text] [Related]
6. Aberrant DNA methylation of PTPRG as one possible mechanism of its under-expression in CML patients in the State of Qatar.
Ismail MA; Samara M; Al Sayab A; Alsharshani M; Yassin MA; Varadharaj G; Vezzalini M; Tomasello L; Monne M; Morsi H; Qoronfleh MW; Zayed H; Cook R; Sorio C; Modjtahedi H; Al-Dewik NI
Mol Genet Genomic Med; 2020 Oct; 8(10):e1319. PubMed ID: 32700424
[TBL] [Abstract][Full Text] [Related]
7. Gene Expression Landscape of Chronic Myeloid Leukemia K562 Cells Overexpressing the Tumor Suppressor Gene PTPRG.
Lombardi G; Latorre RV; Mosca A; Calvanese D; Tomasello L; Boni C; Ferracin M; Negrini M; Dewik NA; Yassin M; Ismail MA; Carpentieri B; Sorio C; Lecca P
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077295
[TBL] [Abstract][Full Text] [Related]
8. Mtss1 is a critical epigenetically regulated tumor suppressor in CML.
Schemionek M; Herrmann O; Reher MM; Chatain N; Schubert C; Costa IG; Hänzelmann S; Gusmao EG; Kintsler S; Braunschweig T; Hamilton A; Helgason GV; Copland M; Schwab A; Müller-Tidow C; Li S; Holyoake TL; Brümmendorf TH; Koschmieder S
Leukemia; 2016 Apr; 30(4):823-32. PubMed ID: 26621336
[TBL] [Abstract][Full Text] [Related]
9. Protein Tyrosine Phosphatase Receptor Gamma as Potential Therapeutic Target for Chronic Myeloid Leukemia Patients.
Ismail MA; Sorio C; Al-Dewik N
Cancer Control; 2022; 29():10732748221140201. PubMed ID: 36382578
[TBL] [Abstract][Full Text] [Related]
10. Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells.
Carlo-Stella C; Regazzi E; Sammarelli G; Colla S; Garau D; Gazit A; Savoldo B; Cilloni D; Tabilio A; Levitzki A; Rizzoli V
Blood; 1999 Jun; 93(11):3973-82. PubMed ID: 10339507
[TBL] [Abstract][Full Text] [Related]
11. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
12. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
13. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
14. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
[TBL] [Abstract][Full Text] [Related]
15. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM
Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of tyrosine kinase inhibitors on a mouse chronic myeloid leukemia model and chronic myeloid leukemia stem cells.
Tanaka Y; Fukushima T; Mikami K; Adachi K; Fukuyama T; Goyama S; Kitamura T
Exp Hematol; 2020 Oct; 90():46-51.e2. PubMed ID: 32910995
[TBL] [Abstract][Full Text] [Related]
17. BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability.
Slupianek A; Falinski R; Znojek P; Stoklosa T; Flis S; Doneddu V; Pytel D; Synowiec E; Blasiak J; Bellacosa A; Skorski T
Leukemia; 2013 Mar; 27(3):629-34. PubMed ID: 23047475
[TBL] [Abstract][Full Text] [Related]
18. CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor-Engineered T Cells.
Warda W; Larosa F; Neto Da Rocha M; Trad R; Deconinck E; Fajloun Z; Faure C; Caillot D; Moldovan M; Valmary-Degano S; Biichle S; Daguindau E; Garnache-Ottou F; Tabruyn S; Adotevi O; Deschamps M; Ferrand C
Cancer Res; 2019 Feb; 79(3):663-675. PubMed ID: 30514753
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.
Carter BZ; Mak PY; Mak DH; Ruvolo VR; Schober W; McQueen T; Cortes J; Kantarjian HM; Champlin RE; Konopleva M; Andreeff M
Oncotarget; 2015 Oct; 6(31):30487-99. PubMed ID: 26431162
[TBL] [Abstract][Full Text] [Related]
20. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.
Herrmann O; Kuepper MK; Bütow M; Costa IG; Appelmann I; Beier F; Luedde T; Braunschweig T; Koschmieder S; Brümmendorf TH; Schemionek M
BMC Cancer; 2019 Jul; 19(1):658. PubMed ID: 31272418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
